An industry veteran, Stein has been with agency for only two years; Bob Temple becomes powerful OND "consultant."
Industry veteran Peter Stein has been named the permanent director of the US FDA's Office of New Drugs after a relatively short tenure as its deputy director.
Center for Drug Evaluation and Research Director Janet Woodcock announced the appointment official Dec. 7 in a memo to staff,...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
